Contrasting Biocorrx (BICX) & Its Rivals

Volatility & Risk

Biocorrx has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Biocorrx’s peers have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.

Profitability

This table compares Biocorrx and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biocorrx	N/A	N/A	-226.71%
Biocorrx Competitors	-747.65%	-29.71%	-13.76%

Insider & Institutional Ownership

57.3% of shares of all “Medical Services” companies are owned by institutional investors. 21.4% of Biocorrx shares are owned by company insiders. Comparatively, 12.9% of shares of all “Medical Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Biocorrx and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biocorrx	$10,000.00	-$5.11 million	-0.88
Biocorrx Competitors	$12.81 billion	$234.98 million	1.86

Biocorrx’s peers have higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Biocorrx peers beat Biocorrx on 6 of the 9 factors compared.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.